Skip to main content

JAK/TYK2

Herpes Zoster on the Brain and Vaccinations: Dr. Kevin Winthrop

Dr. Kevin Winthrop reviews several abstracts that look at herpes zoster infection, including abstracts #0849 and #2002 as presented at the 2020 ACR annual meeting. 

Dr. Tom Appleton and Dr. Peter Nash Highlight OA and PsA Studies

Dr. Janet Pope interviews Dr. Tom Appleton and Dr. Peter Nash about several osteoarthritis and psoriatic arthritis studies presented at the 2020 ACR annual meeting.

Vaccination with Shingrix: Does it work for patients on JAKi?

Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.

RT @Janetbirdope: What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumato

Janet Pope Janetbirdope

2 weeks 3 days ago
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
RT @DrMiniDey: Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadaciti

Mrinalini Dey DrMiniDey

2 weeks 3 days ago
Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5
RT @KDAO2011: Which JAKi will you use after MTX failure? #acr20 @rheumnow

k dao KDAO2011

2 weeks 3 days ago
Which JAKi will you use after MTX failure? #acr20 @rheumnow
RT @RADoctor: Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 2

Jeffrey Curtis RADoctor

2 weeks 3 days ago
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
RT @doctorRBC: Upadacitinib vs. Adalimumab vs. PBO in PsAPhase 3 RCT⬇️MSK symptoms, PsO, function, pain, fatigue,

Robert B Chao, MD doctorRBC

2 weeks 3 days ago

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

RT @DrMiniDey: Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis pati

Mrinalini Dey DrMiniDey

2 weeks 3 days ago
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD
RT @RichardPAConway: Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients tre

Richard Conway RichardPAConway

2 weeks 3 days ago
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
×